RESOURCES & PERSPECTIVES

31. eCOA 101: Why Choose ePRO vs. Paper 9/18/2024

    ePRO solutions enhance data quality, operational efficiency, and patient-centricity in clinical trials by allowing patients to report outcomes digitally instead of using pen and paper.

32. Driving Successful Obesity Drug Development With GLP-1 Agonists 9/18/2024

    GLP-1 agonists are revolutionizing obesity treatment. Signant Health's ePRO solutions support over 30 trials, providing critical patient data and driving successful approvals.

33. Simplify Clinical Trials With Signant SmartSignals® Unified Platform 8/16/2024

    Signant SmartSignals® Unified Platform streamlines clinical trials by integrating eConsent, data collection, remote consultations, and randomization, simplifying workflows for patients and site staff.

34. Clearing The Fog: Optimizing Cancer Trials With Cognitive Assessments 8/16/2024

    Cancer-Related Cognitive Impairment (CRCI) affects cognition during and after treatment. The Signant SmartSignals® CDR System® provides advanced computerized assessments to better manage CRCI.

35. Placebo Response In Clinical Trials: Challenges And Mitigation Strategies 8/16/2024

    Placebo response can impact clinical trial outcomes. Signant Health offers solutions such as eCOA, and tailored training to mitigate these effects and ensure reliable, accurate results.

36. Paper Vs ePRO: Clinical Data Collection Methods 7/16/2024

    Patient-reported outcomes (PROs) assess patients' health without clinician interpretation. Traditional paper methods often result in missing data and quality issues, while electronic solutions enhance data accuracy and completeness.

37. The Case For Cognitive Assessments In Phase 1 Clinical Trials 7/16/2024

    Regulators prioritize patient-reported outcomes. Cognitive assessments in Phase 1 trials detect early drug-related cognitive effects, ensuring safety and efficacy. Signant’s CDR System® is a proven tool for this.

38. Myasthenia Gravis: Reducing Outcome Measures Variability In Trials 7/16/2024

    Myasthenia Gravis is a rare autoimmune disease often unknown to the public. This post explores MG's history, treatment progress, clinical trial challenges, and strategies to reduce outcome variability, improving patient care.

39. Subjective Measures, Objective Outcomes: Data Quality In Atopic Dermatitis Trials 7/16/2024

    Atopic Dermatitis (AD) is a prevalent skin condition. This post explores key measurement tools in AD clinical trials, specifically EASI and Total BSA, highlighting the importance of accurate measurement and strategies to improve data quality.

40. Site Perspectives On BYOD ePRO Use 6/17/2024

    This study examines participant convenience and compliance, aiming to understand and address the challenges faced by site personnel in global trials.